Misplaced Pages

Saridegib: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 04:16, 1 May 2023 editRFZYNSPY (talk | contribs)Extended confirmed users, Rollbackers2,135 edits Replaced broken SMILES string with isomeric smiles from pubchem← Previous edit Revision as of 00:48, 7 May 2023 edit undoLegionMammal978 (talk | contribs)Extended confirmed users7,894 edits move systematic nameNext edit →
Line 6: Line 6:
| ImageSize = | ImageSize =
| IUPACName = ''N''-methanesulfonamide | IUPACName = ''N''-methanesulfonamide
| PIN = ''N''-pyridine-2,9′-naphthoazulen]-3′-yl]methanesulfonamide | SystematicName = ''N''-pyridine-2,9′-naphthoazulen]-3′-yl]methanesulfonamide
| OtherNames = saridegib | OtherNames = saridegib
|Section1={{Chembox Identifiers |Section1={{Chembox Identifiers

Revision as of 00:48, 7 May 2023

Experimental drug
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Saridegib" – news · newspapers · books · scholar · JSTOR (February 2016) (Learn how and when to remove this message)
Saridegib
Names
IUPAC name N-methanesulfonamide
Systematic IUPAC name N-pyridine-2,9′-naphthoazulen]-3′-yl]methanesulfonamide
Other names saridegib
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
IUPHAR/BPS
KEGG
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1Key: HZLFFNCLTRVYJG-WWGOJCOQSA-N
SMILES
  • C1C2((3(O2)CC45CC6C(CC6(5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1
Properties
Chemical formula C29H48N2O3S
Molar mass 504.77 g·mol
Pharmacology
Routes of
administration 		Oral
Legal status
  • Investigational
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). checkY verify (what is  ?) Infobox references
Chemical compound

Saridegib, also known as IPI-926, is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies such as myelofibrosis and ligand-dependent tumors such as chondrosarcoma. IPI-926 exhibits its pharmacological effect by inhibition of the G protein-coupled receptor smoothened, a component of the hedgehog signaling pathway. Chemically, it is a semi-synthetic derivative of the alkaloid cyclopamine. The process begins with cyclopamine extracted from harvested Veratrum californicum which is taken through a series of alterations resulting in an analogue of the natural product cyclopamine, making IPI-926 the only compound in development/testing that is not fully synthetic.

Saridegib is a member of a class of anti-cancer compounds known as hedgehog pathway inhibitors.

References

  1. "Pipeline: IPI-926". Infinity Pharmaceuticals. Archived from the original on 2012-01-19.
  2. ^ Tremblay, MR; Lescarbeau, A; Grogan, MJ; Tan, E; Lin, G; Austad, BC; Yu, LC; Behnke, ML; et al. (2009). "Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)". Journal of Medicinal Chemistry. 52 (14): 4400–18. doi:10.1021/jm900305z. PMID 19522463.
Categories:
Saridegib: Difference between revisions Add topic